Skip to content
Agree.net – Lifestyle
Author:
IRLAB Therapeutics
IRLAB Strengthens Focus On Revenue Generation, Initiates Workforce Reductions, And Announces Reduced Likelihood Of New Partnership Agreements In 2026
November 12, 2026
IRLAB: Invitation to The Interim Report for Q3 2026 Presentation and Webcast
November 6, 2026
The U.S. Patent and Trademark Office Has Issued a Notice of Allowance for A Patent Covering IRLAB’s Drug Candidate IRL1117
October 27, 2026
Nomination Committee Appointed for IRLAB’s Annual General Meeting 2027
October 20, 2026
IRLAB’s Preclinical Research Underpinning Linepemat Published in Peer-Reviewed Journal
October 20, 2026
IRLAB to present at Redeye Theme: Neurology
October 9, 2026
IRLAB Appoints Janne Backman as New Chairman of the Board
September 24, 2026
IRLAB’s CEO Intends to Step Down During the First Quarter of 2027
September 3, 2026
IRLAB: Invitation to The Interim Report for Q2 2026 Presentation and Webcast
August 20, 2026
IRLAB’s Drug Candidate IRL757 Receives the Generic Name Linepemat from The WHO
August 19, 2026
1
2
Next Page
→